Klaus Wanisch

Klaus Wanisch, PhD, currently serves as a Scientist at Addgene since June 2017, following a role as a Technical Service Specialist at Bio-Techne from August 2013 to June 2017. Prior experience includes postdoctoral research positions at Imperial College London and University College London, focusing on bacteriophages for gene therapy in glioblastoma and lentiviral vectors for treating neocortical epilepsy, respectively. Additional postdoctoral work at Royal Holloway, University of London, involved developing iPSC models for spinal muscular atrophy, and early research at the Max Planck Institute of Psychiatry centered on protein synthesis in memory formation. Klaus Wanisch holds a PhD in Neuroscience from Ludwig-Maximilians-Universität München and a Master's degree in Medical Microbiology and Virology from the University of Regensburg. Notable publications include research on mitochondrial deficits in Charcot-Marie-Tooth disease and the effects of protein synthesis inhibition on memory processes.